keyword
MENU ▼
Read by QxMD icon Read
search

Peanut immunotherapy

keyword
https://www.readbyqxmd.com/read/28521317/mechanisms-of-tolerance-induction
#1
Anna Nowak-Węgrzyn, Pantipa Chatchatee
Food allergy results from failure in oral tolerance that usually occurs in infancy or early childhood. Exposure to peanut and hen's egg via the inflamed and disrupted epithelial barrier in children with severe atopic dermatitis is a risk factor for the development of allergy to these foods and supports the hypothesis that epicutaneous exposure in the absence of oral feeding is an important pathway of allergic IgE sensitization in infants. In recent years, the collective evidence has pointed toward the protective effect of an early feeding with peanut and egg in children with eczema, taking advantage of the pathways underlying oral tolerance to counteract epicutaneous exposure...
2017: Annals of Nutrition & Metabolism
https://www.readbyqxmd.com/read/28461822/ige-mediated-food-allergies-in-children-prevalence-triggers-and-management
#2
REVIEW
Sooyoung Lee
Food allergy (FA) is a serious health problem, and severe FA such as food-induced anaphylaxis can often be life threatening. The incidence of FA has been increasing especially in children. They usually develop early in life and affect up to 10% of children. The 2 most common food allergens worldwide are milk and eggs, while the third one varies depending on the countries: peanuts in the United States and Switzerland, wheat in Germany and Japan, tree nuts in Spain, sesame in Israel, and walnuts in Korea. These common food allergens are different and difficult to identify because of differing study methodologies, population, geography, age, and dietary exposure patterns...
April 2017: Korean Journal of Pediatrics
https://www.readbyqxmd.com/read/28423454/uk-neqas-survey-of-allergen-component-testing-across-the-united-kingdom-and-other-european-countries
#3
R Saleem, C Keymer, D Patel, W Egner, A W Rowbottom
The clinical utility of molecular diagnostic approaches in allergy investigation is being recognized increasingly to play a significant role in the management of allergic patients. Determining the sensitization pattern, which is best achieved through the use of component resolved diagnostics (CRD), allows effective risk stratification, appropriate treatment and patient selection for immunotherapy. In order to assess the diagnostic service provisions for in-vitro allergy testing across Europe, a survey was carried out via the total immunoglobulin (Ig)E and specific IgE external quality assurance schemes run by UK National External Quality Assessment Service (NEQAS) Immunology, Immunochemistry and Allergy...
June 2017: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/28421513/primary-prevention-of-food-allergy
#4
REVIEW
Matthew J Greenhawt, David M Fleischer
Food allergy is estimated to affect approximately 8% of children in the USA. This is a disease without any known treatment or cure and, for some, a disease that can be quite severe, even life-threatening. While recent advances in potential treatment have made remarkable strides, with two food-targeted immunotherapy products now in phase III trials, perhaps the biggest gains in the field have come in the advent of potential preventative strategies to avoid the development of food allergy in high-risk individuals...
April 2017: Current Allergy and Asthma Reports
https://www.readbyqxmd.com/read/28397379/b-fahf-2-plus-oral-immunotherapy-oit-is-safer-and-more-effective-than-oit-alone-in-a-murine-model-of-concurrent-peanut-tree-nut-allergy
#5
Kamal D Srivastava, Ying Song, Nan Yang, Changda Liu, Ilan E Goldberg, Anna Nowak-Węgrzyn, Hugh A Sampson, Xiu-Min Li
BACKGROUND: Concurrent sensitization to peanut (PN) and tree nuts (TN), the most dangerous food allergies, is common. Current oral immunotherapy (OIT) is not fully satisfactory. OBJECTIVE: To determine if the herbal formula B-FAHF-2 (BF2) ameliorates PN/TN OIT adverse reactions and enhances persistence of a tolerant state. METHODS: Concurrently sensitized peanut, walnut (WN) and cashew (CSH) allergic mice received 1 day PN/WN/CSH rush OIT plus 3 weeks of maintenance dosing, with or without 3-weeks prior and 3-weeks BF2 co-treatment...
April 11, 2017: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28283151/immunotherapy-for-food-allergy-are-we-there-yet
#6
Yael Gernez, Anna Nowak-Węgrzyn
Current clinical research focuses on food allergen-specific immunotherapy through oral (OIT), sublingual (SLIT), or epicutaneous (EPIT) routes. Immunotherapy relies on the delivery of gradually increasing doses of specific allergens to induce desensitization (defined as temporary antigen hyporesponsiveness that depends on regular food ingestion) and, ultimately, tolerance (defined as the ability to ingest food without symptoms despite prolonged periods of avoidance or irregular intake). Although the majority of the patients treated with OIT achieve desensitization, only a minority achieves tolerance...
March 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28277274/therapeutic-reversal-of-food-allergen-sensitivity-by-mature-retinoic-acid-differentiated-dendritic-cell-induction-of-lag3-cd49b-foxp3-regulatory-t%C3%A2-cells
#7
Wojciech Dawicki, Chunyan Li, Jennifer Town, Xiaobei Zhang, John R Gordon
BACKGROUND: Anaphylaxis is a life-threatening condition for which we have limited therapeutic options. Although specific immunotherapy for food allergies is becoming more effective, it is still laborious and carries substantial risk of adverse events. On the other hand, regulatory dendritic cell (DC) therapy is effective in mouse models of allergic disease and has been shown to work with TH2 cells from atopic asthmatic patients. OBJECTIVE: We assessed whether DC immunotherapy could reverse food allergen sensitivity in mouse models to provide proof of concept relating to their use in the clinic...
May 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28226319/oral-and-sublingual-immunotherapy-potential-causes-for-eosinophilic-gastrointestinal-disorders
#8
REVIEW
Delara Babaie, Mehrnaz Mesdaghi, Makoto Nishino, Mahboubeh Mansouri, Motohiro Ebisawa
Food allergy is a common health problem worldwide, with increasing prevalence during recent decades. The only approved treatments for food allergy are food avoidance and administration of emergency medications in case of accidental exposure, which negatively affects patients' quality of life, so new treatments are highly desirable. Different food immunotherapy modalities have recently been used, with variable success rates in the induction of desensitization and tolerance, and different numbers and types of adverse reactions...
2017: International Archives of Allergy and Immunology
https://www.readbyqxmd.com/read/28212503/lactobacillus-buchneri-s-layer-as-carrier-for-an-ara-h-2-derived-peptide-for-peanut-allergen-specific-immunotherapy
#9
Julia Anzengruber, Merima Bublin, Eva Bönisch, Bettina Janesch, Angelika Tscheppe, Matthias L Braun, Eva-Maria Varga, Christine Hafner, Heimo Breiteneder, Christina Schäffer
Peanut allergy is an IgE-mediated severe hypersensitivity disorder. The lack of a treatment of this potentially fatal allergy has led to intensive research on vaccine development. Here, we describe the design and initial characterization of a carrier-bound peptide derived from the most potent peanut allergen, Ara h 2, as a candidate vaccine. Based on the adjuvant capability of bacterial surface (S-) layers, a fusion protein of the S-layer protein SlpB from Lactobacillus buchneri CD034 and the Ara h 2-derived peptide AH3a42 was produced...
May 2017: Molecular Immunology
https://www.readbyqxmd.com/read/28197701/-innovative-forms-of-specific-immunotherapy
#10
REVIEW
P Zieglmayer
The clinical efficacy of allergen-specific immunotherapy depends on tolerance induction. Treatment success is currently limited by treatment-related adverse reactions. Novel approaches mainly target improvement of tolerability in addition to optimized immunogenicity. For epicutaneous immunotherapy (EPIT), commercially available treatment extracts are applied to skin via a patch. The route exhibits excellent tolerability and good clinical efficacy. The first encouraging data on a peanut EPIT were published in 2016...
February 14, 2017: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/28160513/the-clinical-and-immunological-effects-of-pru-p-3-sublingual-immunotherapy-on-peach-and-peanut-allergy-in-patients-with-systemic-reactions
#11
F Gomez, G Bogas, M Gonzalez, P Campo, M Salas, A Diaz-Perales, M J Rodriguez, A Prieto, D Barber, M Blanca, M J Torres, C Mayorga
BACKGROUND: The peach non-specific lipid transfer protein, Pru p 3, is the primary sensitizer in fruits and responsible for severe reactions in the Mediterranean area. Peach allergy is frequently associated with other allergies such as peanut. Therefore, it is important to assess how specific immunotherapy to Pru p 3 could affect both peach and peanut tolerance. OBJECTIVES: To evaluate peach and peanut desensitization and immunological changes after 1 year of Pru p 3 sublingual immunotherapy (SLIT) in patients with systemic allergic reactions to peach and/or peanut...
March 2017: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28132800/preparation-and-analysis-of-peanut-flour-used-in-oral-immunotherapy-clinical-trials
#12
Jelena P Berglund, Nicole Szczepanski, Anusha Penumarti, Ayeshia Beavers, Janelle Kesselring, Kelly Orgel, Bruce Burnett, A Wesley Burks, Michael Kulis
BACKGROUND: Oral immunotherapy (OIT) is an investigational therapeutic approach for the treatment of food allergies. Characterization of the drug product used in oral immunotherapy trials for peanut allergy has not been reported. OBJECTIVE: To quantify relative amounts of the major peanut allergens and microbial load present in peanut flour used in OIT trials and assess whether these parameters change over a 12-month period. We also anticipate that this report will serve as a guide for investigators seeking to conduct OIT trials under Food and Drug Administration-approved Investigational New Drug applications...
January 26, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28100257/food-specific-sublingual-immunotherapy-is-well-tolerated-and-safe-in-healthy-dogs-a-blind-randomized-placebo-controlled-study
#13
RANDOMIZED CONTROLLED TRIAL
E Maina, M Pelst, M Hesta, E Cox
BACKGROUND: Food allergies are increasing in prevalence but no treatment strategies are currently available to cure dogs with food allergy. Over the past decade, experimental food allergen-specific sublingual immunotherapy (FA-SLIT) has emerged as a potential treatment for food allergies in human medicine. However, FA-SLIT has not been investigated in dogs. Therefore, the objective of this study was to prospectively evaluate the safety, tolerability and dispenser sterility of FA-SLIT in healthy dogs before testing it in food allergic dogs...
January 18, 2017: BMC Veterinary Research
https://www.readbyqxmd.com/read/28091362/epicutaneous-immunotherapy-for-the-treatment-of-peanut-allergy-in-children-and-young-adults
#14
Stacie M Jones, Scott H Sicherer, A Wesley Burks, Donald Y M Leung, Robert W Lindblad, Peter Dawson, Alice K Henning, M Cecilia Berin, David Chiang, Brian P Vickery, Robbie D Pesek, Christine B Cho, Wendy F Davidson, Marshall Plaut, Hugh A Sampson, Robert A Wood
BACKGROUND: Peanut allergy is common, life-threatening, and without therapeutic options. We evaluated peanut epicutaneous immunotherapy (EPIT) by using Viaskin Peanut for peanut allergy treatment. OBJECTIVE: We sought to evaluate the clinical, safety, and immunologic effects of EPIT for the treatment of peanut allergy. METHODS: In this multicenter, double-blind, randomized, placebo-controlled study, 74 participants with peanut allergy (ages 4-25 years) were treated with placebo (n = 25), Viaskin Peanut 100 μg (VP100; n = 24) or Viaskin Peanut 250 μg (VP250; n = 25; DBV Technologies, Montrouge, France)...
April 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28042528/desensitization-for-peanut-allergies-in-children
#15
Rekha D Jhamnani, Pamela Frischmeyer-Guerrerio
Immunotherapy for peanut allergy has been an exploding topic of study within the last few years. Sublingual, epicutaneous, and oral immunotherapy are being investigated and show promise in the treatment of peanut allergy. Oral immunotherapy has shown the most clinical benefit; however, sublingual and epicutaneous immunotherapy appear to have the most favorable safety profiles. Most studies to date suggest that only a minority of subjects achieve sustained unresponsiveness to peanut after discontinuation of immunotherapy...
September 2016: Current Treatment Options in Allergy
https://www.readbyqxmd.com/read/28017628/eosinophilic-esophagitis-during-peanut-oral-immunotherapy-with-omalizumab
#16
Caitlin M Burk, Evan S Dellon, Pamela H Steele, Yamini V Virkud, Mike Kulis, A Wesley Burks, Brian P Vickery
No abstract text is available yet for this article.
March 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/27957697/benefit-of-slit-and-scit-for-allergic-rhinitis-and-asthma
#17
REVIEW
Giovanni Passalacqua, Giorgio Walter Canonica, Diego Bagnasco
Allergen immunotherapy (AIT) has been in use since more than one century, when Leonard Noon experimentally proved its efficacy in hayfever (Noon, in Lancet 1:1572-3, 1911). Since then, AIT was administered only as subcutaneous injections (SCIT) until the sublingual route (SLIT) was proposed in 1986. The use of SLIT was proposed following several surveys from the USA and UK that repeatedly reported fatalities due to SCIT (Lockey et al. in J Allergy Clin Immunol 75(1): 166, 1985; Lockey et al. in J Allergy Clin Immunol 660-77, 1985; Committee on the safety of medicines...
November 2016: Current Allergy and Asthma Reports
https://www.readbyqxmd.com/read/27931280/safety-profile-of-oral-immunotherapy-with-cows-milk-and-hen-egg-a-10-year-experience-in-controlled-trials
#18
Giovanni B Pajno, Lucia Caminiti, Fernanda Chiera, Giuseppe Crisafulli, Giuseppina Salzano, Stefania Arasi, Giovanni Passalacqua
BACKGROUND: Oral immunotherapy (OIT) for food allergy is gaining interest due to the favorable clinical results reported with cow's milk, hen egg and peanut. The safety of the procedure remains a critical aspect that can limit the introduction of OIT in clinical practice. OBJECTIVE: We described herein, in detail, the occurrence and characteristics of adverse events (AE) with OIT in children who participated in controlled trials at our unit. METHODS: The clinical records of 68 children who received active treatment (40 for cow's milk and 28 for hen egg) were carefully reviewed...
September 2016: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/27916627/peanut-oral-immunotherapy-decreases-ige-to-ara-h-2-and-ara-h-6-but-does-not-enhance-sensitization-to-cross-reactive-allergens
#19
Riikka Uotila, Anna Kaarina Kukkonen, Dario Greco, Anna Susanna Pelkonen, Mika Juhani Mäkelä
No abstract text is available yet for this article.
April 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/27859599/double-blind-placebo-controlled-challenge-showed-that-peanut-oral-immunotherapy-was-effective-for-severe-allergy-without-negative-effects-on%C3%A2-airway-inflammation
#20
Anna Kaarina Kukkonen, Riikka Uotila, Leo Pekka Malmberg, Anna Susanna Pelkonen, Mika Juhani Mäkelä
AIM: This study examined the efficacy and the safety of peanut oral immunotherapy (OIT). METHODS: We recruited 60 patients aged six years to 18 years who had a moderate-to-severe reaction to a double-blind placebo-controlled peanut challenge: 39 received OIT during an eight-month build-up phase and maintenance phase and 21 controls avoided peanuts. We measured specific immunoglobulin E and G4 (IgE and IgG4) to peanuts and to Ara h 1, 2, 3, 8 and 9 and monitored adverse events, bronchial hyper-responsiveness (BHR) to methacholine and fractional concentrations of exhaled nitric oxide (FeNO)...
February 2017: Acta Paediatrica
keyword
keyword
113759
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"